Investing isn't easy. Even Warren Buffett counsels that most investors should invest in a low-cost index like the S&P 500. That way, "you'll be buying into a wonderful industry, which in effect is all of American industry," he says.
But there are, of course, companies whose long-term fortunes differ substantially from the index. In this series, we look at how individual stocks have performed against the broad S&P 500.
Step on up, Diebold (NYSE:DBD).
Diebold shares have underperformed the S&P 500 over the past quarter-century:
Since 1987, shares have returned an average of 8.3% a year, compared with 9.7% a year for the S&P (both include dividends). One thousand dollars invested in the S&P in 1987 would be worth $19,200 today. In Diebold, it'd be worth $13,000.
Dividends accounted for a lot of those gains. Compounded since 1987, dividends have made up about half of Diebold's returns. For the S&P, dividends account for 39% of total returns.
Now have a look at how Diebold earnings compare with S&P 500 earnings:
Some underperformance here, too. Since 1995, Diebold's earnings per share have grown by an average of 3.8% a year, compared with 6% a year for the broader index.
What's that meant for valuations? Diebold has traded for an average of 23 times earnings since 1987 -- just below the 24 times earnings for the broader S&P 500.
Through it all, shares have been slight disappointments over the past quarter-century.
Of course, the important question is whether that will continue. That's where you come in. Our CAPS community currently ranks Diebold with a four-star rating (out of five). Care to disagree? Leave your thoughts in the comment section below, or add Diebold to My Watchlist.
Fool contributor Morgan Housel and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What's Juno Therapeutics Worth to Celgene?
Celgene may be considering a multibillion-dollar bid to acquire Juno.
Why Ascena Retail Group Inc. Stock Plunged 62% in 2017
The parent company of maurices just finished a tough year. Here's what investors need to know.
3 Easy Ways to Invest in India for 2018
Here's how to get access to this exciting emerging market.